BPC-157 is a synthetic peptide made up of 15 amino acids, derived from a protective protein naturally found in human gastric (stomach) juice. The name stands for “Body Protection Compound,” and it was first described in 1993 as a peptide with beneficial effects on the gastrointestinal tract. Since then, it has generated significant interest for its apparent ability to accelerate healing in tendons, muscles, the gut lining, and even nerve tissue, though nearly all of this evidence comes from animal studies rather than human clinical trials.
The peptide’s amino acid sequence (GEPPPGKPADDAGLV) is produced through chemical synthesis, making it widely available in research settings. It has been described as a hormone-like gastric protectant that stimulates wound repair, with no reported toxicity in animal models. Despite this promising profile, BPC-157 has no approved medical use in the United States, and its regulatory status has tightened considerably in recent years.
How BPC-157 Works in the Body
BPC-157’s healing effects appear to center on one key process: growing new blood vessels. The peptide boosts the activity of a receptor that drives blood vessel formation, increasing the production of nitric oxide, a molecule your body uses to widen blood vessels and support the growth of new capillaries. This is particularly relevant for tissues that have poor blood supply, like tendons and ligaments, where slow circulation is a major reason injuries take so long to heal.
Beyond blood vessel growth, BPC-157 ramps up the body’s own antioxidant defenses. It increases production of a protective enzyme that reduces oxidative stress, prevents damage to the energy-producing structures inside cells, and limits the kind of programmed cell death that worsens injuries. In cell studies, the peptide triggers a dose-dependent increase in signals that drive cell multiplication, migration, and the formation of tube-like structures that become new blood vessels.
For connective tissue specifically, BPC-157 appears to stimulate the cells that build tendons and ligaments (fibroblasts) to multiply faster and produce more collagen, the structural protein that gives these tissues their strength.
Tendon and Muscle Repair
The most studied application of BPC-157 is musculoskeletal healing. In rats with fully severed Achilles tendons, the peptide produced improvements across every measure researchers tested. Treated animals showed greater load-bearing capacity, better elasticity, and superior functional recovery compared to controls. Under a microscope, the healing tissue contained more of the cells and structural fibers associated with strong repair, including increased fibroblast formation, reticulin, and collagen. The tendon defects were smaller and shallower, and full tendon integrity was eventually restored.
These results held at both microgram and nanogram doses, suggesting the peptide is active even in very small amounts. Control animals, by contrast, followed the typical impaired healing pattern seen after Achilles tendon transection, with large defects persisting between the cut ends.
Gut Protection and Repair
Given its origin in gastric juice, it’s not surprising that BPC-157 shows strong effects in the digestive tract. In rat models of ischemic colitis (where blood supply to a segment of the colon is cut off), the peptide rapidly restored blood flow to the injured area by activating collateral blood vessels that bypassed the blockage. Treated animals showed preserved mucosal folds, dramatically smaller areas of pale, damaged tissue, and normalized levels of oxidative stress markers.
Even when applied later, after the blood supply had already been blocked and additional obstruction was introduced, BPC-157 still produced significant improvement. By day 10 of treatment, rats had almost completely intact mucosa with no visible tissue defects, normal colon diameter, and only minor adhesions. The peptide has also been used in clinical trials for ulcerative colitis, though published human outcome data remains limited.
Effects on the Nervous System
BPC-157 shows neuroprotective properties that extend well beyond the gut. In animal studies, it protects sensory neurons, improves nerve regeneration after a peripheral nerve is severed, and reduces the self-harming behavior (autotomy) that animals typically develop after nerve injuries. After traumatic brain injury in rats, the peptide slowed the progression of damage and helped counteract the cascade of secondary injury that typically follows the initial trauma.
In spinal cord compression models where rats developed tail paralysis, BPC-157 reduced nerve cell death, demyelination (loss of the protective nerve coating), and cyst formation while rescuing tail function in both short-term and long-term observation periods. The peptide also stabilizes the connections between nerves and muscles, effectively maintaining communication at the junction where nerve signals tell muscles to contract.
How It’s Administered
In animal research, BPC-157 has been given by injection (intravenous, intramuscular, and into the abdominal cavity) and applied topically as a bath to exposed tissue. Pharmacokinetic studies in rats and dogs show it moves quickly through the body. After intramuscular injection in dogs, peak blood levels are reached within about 6 to 9 minutes, and the peptide’s half-life after intravenous administration is just over 5 minutes, meaning it clears the bloodstream rapidly.
The effective dose range in animal studies is roughly 6 to 50 micrograms per kilogram of body weight. Researchers have proposed a clinical dose of 200 micrograms per person per day for potential human use, based on body surface area conversions from animal data. However, no standardized human dosing protocol exists because no human trials have established safe and effective doses.
Outside of research, people have used BPC-157 through subcutaneous injections and oral capsules. Oral administration is notable because the peptide is remarkably stable in stomach acid, which is unusual for a peptide (most are broken down before they can be absorbed). This stability makes intuitive sense given that the compound originates in gastric juice.
Regulatory Status and Bans
BPC-157 has no FDA-approved indication for any condition. In 2023, the FDA classified it as a Category 2 bulk drug substance, meaning it raises significant safety concerns and cannot be compounded by commercial pharmacies. The agency’s position is that there is insufficient evidence to determine whether it would cause harm to humans.
The athletic world has been even more aggressive. The World Anti-Doping Agency (WADA) specifically banned BPC-157 in 2022, placing it under the S0 Unapproved Substances category of its Prohibited List. The NFL and UFC followed with their own specific bans the same year. The U.S. Anti-Doping Agency explicitly identifies BPC-157 as a prohibited experimental peptide. For any competitive athlete, using BPC-157 risks a doping violation regardless of the sport.
Safety Concerns
Animal studies have consistently reported no toxicity from BPC-157, which is part of what makes it unusual among bioactive peptides. However, “no toxicity in rats” is a very different statement from “safe for humans.” The absence of completed, published human safety trials means the actual risk profile in people is unknown.
The peptide’s powerful ability to stimulate blood vessel growth raises theoretical concerns. Any substance that strongly promotes the formation of new blood vessels could, in theory, support the growth of tumors or worsen conditions where abnormal blood vessel growth is already a problem. This hasn’t been demonstrated with BPC-157, but it also hasn’t been ruled out through the kind of long-term safety monitoring that FDA-approved drugs undergo.
Products sold online present additional risks. Without FDA oversight of manufacturing, there is no guarantee that what’s on the label matches what’s in the vial. Contamination, incorrect concentrations, and degraded peptide are all possibilities with unregulated sources.